leadf
logo-loader
viewOrthocell Ltd

Orthocell Ltd secures new US divisional patent for CelGro®

Orthocell Ltd's (ASX:OCC) Paul Anderson talks Proactive's Andrew Scott through a new US divisional patent they've secured for CelGro® that covers the method of manufacture of collagen medical devices and as an aid in the surgical repair of soft tissue injuries. Orthocell has already been granted patents for CelGro® in the US, Canada, Europe, China, Japan, Singapore, Australia and New Zealand with CelGro® dental (recently renamed Striate+) approved for use in the US, Europe and Australia.

Quick facts: Orthocell Ltd

Price: 0.49 AUD

ASX:OCC
Market: ASX
Market Cap: $92.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell says Australian reimbursement for CelGro® Dental is important...

Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive's Andrew Scott soon after receiving notification from the Australian Government Department of Health that CelGro® Dental has been included on the Australian Prostheses List. Inclusion on the prostheses list enables dental practitioners...

3 hours, 50 minutes ago

2 min read